Evidence map›Paper›PMID 41620477›Full record

ArticleScientific reports2026

Metabolomic-driven prediction of the mutational status of healthy individuals with a family history of hereditary breast and ovarian cancer syndrome: the HRRmet study.

Bàrbara Roig, Sara Fernández-Castillejo, Josep Gumà, Joan Badia, Mireia Melé, Mònica Salvat, Montserrat Querol, Raquel Cumeras, Marta Rodríguez-Balada

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bàrbara RoigInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.
Sara Fernández-CastillejoInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain. sara.fernandez@iispv.cat.
Josep GumàInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.
Joan BadiaInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.
Mireia MeléInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.
Mònica SalvatInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.
Montserrat QuerolInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.
Raquel CumerasInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.
Marta Rodríguez-BaladaInstitute of Oncology of Southern Catalonia (IOCS), Sant Joan University Hospital of Reus (HUSJR), Reus, Spain.

Funding

Lliga contra el Càncer, Comarques de Tarragona i Terres de l'Ebre Ref PR-010-2022
6 · The paper itself

Abstract

Pathogenic variants (PVs) identified in genes involved in the DNA homologous recombination repair (HRR) mechanism are the main cause of hereditary breast and ovarian cancer syndrome (HBOC). The main objective of this study was to identify differential plasma metabolomic profiles associated with the HRR genotype in healthy individuals. Cascade testing was performed by Sanger sequencing in healthy carrier and noncarrier individuals with a familial history of HBOC. PVs associated with HRR genes (BRCA1, BRCA2, PALB2, ATM, CHEK2 and RAD51) were identified. Untargeted metabolomics of plasma samples was performed by liquid chromatography coupled with mass spectrometry. Predictive models were developed using a machine learning approach. Thirty-one metabolites were selected to create the global predictive model (accuracy 61.9%), whereas the gene-specific models had a better performance (accuracy > 80%) and were constructed with fewer metabolites. The present study is the first to characterize the phenotype associated with the HRR-deficient genotype in healthy individuals with a familial history of HBOC. Metabolomic profiles may be useful for differentiating carriers from noncarriers of PVs in the HRR genes, and therefore, with potential predictive capacity of the HRR germline mutational status.

Indexed as

Hereditary Breast and Ovarian Cancer SyndromeMetabolomeMetabolomicsMutationAdultFemaleGenetic Predisposition to DiseaseGenotypeHumansMiddle AgedHereditary breast and ovarian cancerHomologous recombination repairMetabolomeMetabolomic profileMutational status

Identifiers

PMID41620477
PMCPMC12917145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.